NICE-squareNICE released the Appraisal Consultation Document (ACD) on biologic DMARDS used in the treatment of Rheumatoid Arthritis (RA) on 19th June. The main recommendation of the ACD supports the current position that the drugs remain available only to those most severely affected. Although this is welcomed a joint statement by NRAS, BSR and Arthritis Care highlights the missed opportunity to improve patient care and extend the use of such drugs for people with moderate disease.

Leave a Reply

Your email address will not be published. Required fields are marked *